Trials / Completed
CompletedNCT00396799
Bioequivalence Study Of Bazedoxifene/Conjugated Estrogen Tablets In Postmenopausal Women
An Open-Label, Single-Dose, Randomized-to-Sequence, 2-Period, Crossover, Pivotal Bioequivalence Study Between Bazedoxifene Acetate/Conjugated Estrogens (Premarin Current Process) and Bazedoxifene Acetate/Conjugated Estrogens (Premarin New Process) Tablets Administered to Healthy Postmenopausal Women
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Female
- Age
- 35 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The primary objective is to evaluate the bioequivalence between bazedoxifene/conjugated estrogens tablets produced using the current manufacturing process to bazedoxifene/conjugated estrogens tablets produced using a new manufacturing process
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bazedoxifene/conjugated estrogens |
Timeline
- Start date
- 2006-11-01
- Completion
- 2006-11-01
- First posted
- 2006-11-08
- Last updated
- 2007-03-13
Source: ClinicalTrials.gov record NCT00396799. Inclusion in this directory is not an endorsement.